As of November 10, 2026, ArriVent BioPharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 9, 2026 (Form 8-K, November 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like ArriVent BioPharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
ArriVent BioPharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-09. Every row below is cited to the filing it comes from, and this page adds each new change as ArriVent BioPharma, Inc. files it.
Also on the record for ArriVent BioPharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.8% of the class | 5%+ stakes | Source |
| October 13, 2026 | Stake report, Schedule 13G, by Vivo Opportunity, LLC | 5% of the class | 5%+ stakes | Source |
| October 8, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 5.8% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.8% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 6.8% of the class | 5%+ stakes | Source |
| March 5, 2026 | Stake report, Schedule 13G/A, by Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Hillhouse Investment Management, Ltd. | 9.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by INFINITUM ASSET MANAGEMENT, LLC | 9.9% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.52% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | 4.9% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 8.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs ArriVent BioPharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on ArriVent BioPharma, Inc. and the records around it.
ArriVent BioPharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners XI, L.P. ("SVP XI") also filed stake reports on 1 other company: NextCure, Inc. (Mar 2026)
- Hillhouse Investment Management, Ltd. also filed stake reports on 2 other companies: Smart Share Global Limited (May 2026), Webull Corp (Feb 2026)
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026)
Watch ArriVent BioPharma, Inc.
Get an email when ArriVent BioPharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ArriVent BioPharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ArriVent BioPharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ArriVent BioPharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | Reported | not named in the filing | 8-K, 2026-11-09 |
New leaders reset buying decisions — get the Full Report on ArriVent BioPharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at ArriVent BioPharma, Inc., with the record behind each one.
Find candidates like senior executive at ArriVent BioPharma, Inc.Every change, in the filing's words
Reported
On November 6, 2026, Stuart Lutzker, M.D., Ph.D. notified the Company of his intention to retire from the position of President, Research and Development of the Company and as a director of the Company, effective as of December 1, 2026 (the "Retirement Date").
- Dr. Lutzker's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- In connection with Dr. Lutzker's retirement from the Company, the Company intends to enter into a retirement agreement with Dr. Lutzker (the "Retirement Agreement").
- Under the terms of the Retirement Agreement, the Company would pay Dr. Lutzker, in consideration for, among other things, his performance of duties requested by the Company until the Retirement Date, his compliance with certain restrictive covenants, and a typical release of claims, a one-time payment of $428,438.21.
- In connection with Dr. Lutzker's departure, the Company also announced that Priti Patel, M.D., the Company's Chief Medical Officer, will be assuming the role and responsibility of leading the Company's research and development function, effective as of December 1, 2026.
- Dr. Patel, age 51, is an experienced biopharmaceutical executive with extensive expertise in clinical development, oncology, and hematology drug development.
- She brings a strong track record of leadership in advancing clinical development programs and shaping medical and clinical strategies across biotechnology and pharmaceutical organizations.
Tools for this story
Each opens in a new tab, filled in for ArriVent BioPharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.